The National Review included Horizon’s work tracking drugmakers responses to the Inflation Reduction Act’s drug pricing negotiation rule, in a recent article titled, “As Predicted, Patients Are Paying the Price for the Inflation Reduction Act’s Drug Reform.”
According to a recent Horizon report, biotech corporation Insmed and Acadia Pharmaceuticals are expected to end their work on the bronchiectasis drug brensocatib and the psychosis treatment pimavanserin, respectively.